Skip to main content
IMDX
NASDAQ Life Sciences

GraftassuredxがFDA提作へより走了る丬のスタートを赴了ている。Insight Molecular Diagnosticsがキーマイレストールを完了

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$4.94
Mkt Cap
$158.806M
52W Low
$2.33
52W High
$8.51
Market data snapshot near publication time

summarizeSummary

Insight Molecular Diagnostics Inc.がするのGraftassuredxプロダクトのキーマイレストールを完了したるが終了。これはクンパネイのもちの好もな消動です。すでは、最初にQuest Diagnosticsよりの終了に幸さる核式スペシモン放競変顥が完了さるたが、ひたるテステまの渡のサービスの放競橜定を带さるかになる。これのサイズのクンパネイには、プロダクトを改渐別群推論へより走了するはマテリアルのイベントです。テレーダーは、終了に幸さるFDA提作をまとるたのために、終了の改渐別群推論をまとるたのために当たなカタリストを観気しなことが。

この発表時点で、IMDXは$4.94で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$1.6億でした。 52週の取引レンジは$2.33から$8.51でした。 このニュースはポジティブの市場センチメント、重要度スコア8/10と評価されました。 出典：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed IMDX - Latest Insights

IMDX
Apr 27, 2026, 7:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Broadwood Partners Increases Stake to 39.7%, Signals Intent for Shareholder Value Creation
Sentiment: Positive
View Wiseek Article
IMDX
Apr 27, 2026, 7:08 PM EDT
Filing Type: 4
Importance Score:
9
Broadwood Partners, a 10% owner, significantly increases stake in Insight Molecular Diagnostics with over $2M in new purchases
Sentiment: Positive
View Wiseek Article
IMDX
Apr 20, 2026, 7:24 PM EDT
Filing Type: 4
Importance Score:
8
10% Owner Broadwood Partners Increases Stake with $652K Open Market Purchase
Sentiment: Positive
View Wiseek Article
IMDX
Apr 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
iMDx's GraftAssure Assay Gains Momentum with New Clinical Data, FDA Submission Details
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:13 PM EDT
Filing Type: 10-K
Importance Score:
8
Insight Molecular Diagnostics Resolves Going Concern, Secures $24.6M in New Capital, and Submits Key Product to FDA
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Insight Molecular Diagnostics Submits Key Transplant Diagnostic for FDA Review, Reports Q4 Results
Sentiment: Positive
View Wiseek Article
IMDX
Mar 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Second Study Affirms iMDx GraftAssure Superiority, Enabling First-Ever Transplant Rejection 'Rule-In' Option
Sentiment: Positive
View Wiseek Article
IMDX
Mar 03, 2026, 8:07 AM EST
Source: Reuters
Importance Score:
8
Graftassuredx Advances Toward FDA Submission as Insight Molecular Diagnostics Completes Key Milestones
Sentiment: Positive
View Wiseek Article
IMDX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Insight Molecular Diagnostics Partners with Quest Diagnostics for GraftAssureCore™ Test Collection
Sentiment: Positive
View Wiseek Article
IMDX
Feb 12, 2026, 7:52 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Activist Investor Broadwood Partners Increases Stake to 37.4% with $3M Premium Purchase
Sentiment: Positive
View Wiseek Article